Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | TTX-MC138 |
| Synonyms | |
| Therapy Description |
TTX-MC138 comprises anti-miR-10b antagomirs linked to iron oxide nanoparticles, which potentially inhibits tumor growth (Cancer Res (2023) 83 (7_Supplement): 548). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TTX-MC138 | TTX MC138|TTXMC138 | TTX-MC138 comprises anti-miR-10b antagomirs linked to iron oxide nanoparticles, which potentially inhibits tumor growth (Cancer Res (2023) 83 (7_Supplement): 548). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06260774 | Phase Ib/II | TTX-MC138 | Study of TTX-MC138 in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | 0 |